Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Relapsed or Refractory DLBCL (LOTIS-5)
NCT04384484Phase 3Active, not recruiting
- Sponsor
- ADC Therapeutics
- Start
- Sep 2020
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by ADC Therapeutics. Primary endpoint: Progression-free Survival up to 4 years. Started Sep 2020; status: active, not recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04384484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04384484.